When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AKRO - Mid-stage study underway for Akero's NASH candidate AKR-001
Akero Therapeutics Inc.
The first patient has been dosed in a Phase 2a clinical trial, BALANCED, evaluating Akero Therapeutics' (NASDAQ:AKRO) lead candidate AKR-001 for the treatment of nonalcoholic steatohepatitis (NASH).
More news on: Akero Therapeutics, Inc., Healthcare stocks news,